Pharma industry wants Australia's price cut bill to be passed in November
This article was originally published in SRA
Brendan Shaw, chief executive of R&D industry association Medicines Australia, has said that he hopes that Australia's medicines pricing bill – which targets savings of A$1.86 billion (US$1.86 billion) over five years – will be approved this month because one of its key provisions, namely the disclosure of the prices of the less innovative drugs in the F2 formulary, is expected to start on 1 December1.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.